

# VON SOOSTEN, LAURA, M.SC.

## GENERAL INFORMATION



### PhD Student

Hopp Children's Cancer Center at the NCT Heidelberg (KITZ)  
German Cancer Research Center (DKFZ), Division of Pediatric Glioma  
Research and Division of Pediatric Neurooncology, Preclinical modeling  
Group  
Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

A02

## ACADEMIC EDUCATION & QUALIFICATION

Year(s)	Education
2016 - 2018	Master of Science in Engineering in Biotechnology, Aalborg Universitet, Denmark
2012 - 2016	Bachelor of Science in Biotechnology and Process Engineering, Hochschule Flensburg, Germany

## PROFESSIONAL EXPERIENCE

Year(s)	Experience
2020 - present	Doctoral researcher, Division of Pediatric Glioma Research and Division of Pediatric Neurooncology, DKFZ
2019 - 2020	Biotechnologist/Bioengineer, Division of Pediatric Glioma Research, DKFZ

## OTHER QUALIFICATIONS/ROLES/RESPONSIBILITIES

Year(s)	Qualifications/Roles/Responsibilities
2020	Co-applicant SWISS BRIDGE Award 2020
2019	Ian's Friends Foundation, WhatIFF grant
2018	DAAD „Forschungsstipendium für promovierte Nachwuchswissenschaftler“

## SELECTED PUBLICATIONS

1. Sigaud R, Rösch L, Gatzweiler C, Benzel J, von Soosten L, Peterziel H, Selt F, Najafi S, Ayhan S, Gerloff XF, Hofmann N, Büdenbender I, Schmitt L, Foerster KI, Burhenne J, Haefeli WE, Korshunov A, Sahm F, van Tilburg CM, Jones DTW, Pfister SM, Knoerzer D, Kreider BL, Sauter M, Pajtler KW, Zuckermann M, Oehme I, Witt O, Milde T. The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models. **Neuro Oncol.** 2023 Mar 14;25(3):566-579.